Form 4: United Therapeutics Exec Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, engaged in transactions on June 15, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The exercise of stock options resulted in the acquisition of 9,500 shares at a price of $146.03 per share.
• Following these transactions, Rothblatt's beneficial ownership of common stock directly held is 41,433 shares.
• Additional shares are held indirectly through a spouse and various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine insider transactions conducted under a pre-established plan, rather than indicating significant new company performance or strategic shifts.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating a pre-determined strategy for stock sales.
• The plan is designed to satisfy affirmative defense conditions, suggesting adherence to regulatory guidelines.
• The reporting person continues to hold a significant number of shares indirectly through trusts and a spouse.

Negatives

• A substantial number of shares (over 100,000) were disposed of through sales.
• The sales occurred at prices significantly higher than the exercise price of the stock options, indicating a profit-taking scenario.

Risks

• The plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, indicating a potential for further sales.
• The weighted average sale prices ranged from $538.60 to $554.06, indicating a significant value of shares sold.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever comes first. This suggests potential for further stock option exercises and sales within this timeframe.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
• The reporting person undertakes to provide full information regarding the number of shares and prices at which transactions were effected upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a 10b5-1 plan by a CEO of a biotechnology company like United Therapeutics is a common practice to manage stock sales in a way that avoids insider trading concerns, especially given the often volatile nature of biotech stock prices.

Stakeholder Impact

• Shareholders may observe insider selling, which can sometimes be perceived negatively, though the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees holding stock options may be influenced by the exercise and sale patterns of senior management.
• The company's stock price may experience minor fluctuations due to the volume of shares traded by a key executive.

Next Steps

• Continue executing the 10b5-1 trading plan until its termination conditions are met.
• Monitor future Form 4 filings for additional insider transactions.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Martine A. Rothblatt, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Common Stock